Evaluation of multiple-flows exhaled nitric oxide in idiopathic and non-idiopathic interstitial lung disease.


Journal

Journal of breath research
ISSN: 1752-7163
Titre abrégé: J Breath Res
Pays: England
ID NLM: 101463871

Informations de publication

Date de publication:
27 03 2019
Historique:
pubmed: 29 1 2019
medline: 24 12 2019
entrez: 29 1 2019
Statut: epublish

Résumé

fractional exhaled nitric oxide (FeNO) is a non-invasive and reproducible marker of nitrosative stress and lung inflammation. More recently, FeNO has been proposed as a marker of severity of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis associated ILD. to evaluate the role of FeNO in the diagnostic pathway of ILDs. according to ERS guidelines for exhaled biomarkers in lung diseases, FeNO at multiple flow-rates (50-100-150 and 350 ml s all ILD groups reported higher levels of FeNO 150-350 ml s patients affected by ILD reported increased FeNO 150-350 ml s

Sections du résumé

BACKGROUND
fractional exhaled nitric oxide (FeNO) is a non-invasive and reproducible marker of nitrosative stress and lung inflammation. More recently, FeNO has been proposed as a marker of severity of idiopathic pulmonary fibrosis (IPF) and systemic sclerosis associated ILD.
AIM AND OBJECTIVES
to evaluate the role of FeNO in the diagnostic pathway of ILDs.
METHODS
according to ERS guidelines for exhaled biomarkers in lung diseases, FeNO at multiple flow-rates (50-100-150 and 350 ml s
RESULTS
all ILD groups reported higher levels of FeNO 150-350 ml s
CONCLUSIONS
patients affected by ILD reported increased FeNO 150-350 ml s

Identifiants

pubmed: 30690441
doi: 10.1088/1752-7163/ab0233
doi:

Substances chimiques

Nitric Oxide 31C4KY9ESH

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

026008

Auteurs

Paolo Cameli (P)

Department of Medical and Surgical Sciences and Neurosciences, Respiratory Disease and Lung Transplantation Unity, University of Siena, Siena, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH